1. From: Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Arch Intern Med. 2004;164(13): doi: /archinte
Figure Legend:
Figure 1. Statin therapy vs placebo use: relative risk for coronary heart disease mortality or nonfatal myocardial infarction. RR indicates relative risk; CI, confidence interval; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty. For expansions of trial names, see the reference list.
Date of download: 10/12/2017

2. From: Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Arch Intern Med. 2004;164(13): doi: /archinte
Figure Legend:
Figure 2. Statin therapy vs placebo use: relative risk for all-cause mortality. RR indicates relative risk; CI, confidence interval; PTCA, percutaneous transluminal coronary angioplasty. For expansions of trial names, see the reference list.
Date of download: 10/12/2017

3. From: Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Arch Intern Med. 2004;164(13): doi: /archinte
Figure Legend:
Figure 3. Relative risk from the meta-regression model for coronary heart disease mortality or myocardial infarction. Analyses were limited to placebo-controlled statin trials of at least 1-year duration that reported the respective outcome measures. The analyses used low-density lipoprotein cholesterol (LDL-C) subgroup data from the trials that reported that information. The models provide outcome estimates for statin therapy vs placebo use for a 5½-year period (midrange of trial follow-up for most included study groups) across a range of values for the typical or average baseline LDL-C level. To convert LDL-C from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by For expansions of trial names, see the reference list.
Date of download: 10/12/2017

4. From: Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Arch Intern Med. 2004;164(13): doi: /archinte
Figure Legend:
Figure 4. Relative risk from meta-regression model for major cardiac events. Analyses were limited to placebo-controlled statin trials of at least 1-year duration that reported the respective outcome measures. The analyses used low-density lipoprotein cholesterol (LDL-C) subgroup data from the trials that reported that information. The models provide outcome estimates for statin therapy vs placebo use for a 5½-year period (midrange of trial follow-up for most included study groups) across a range of values for the typical or average baseline LDL-C level. To convert LDL-C from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by For expansions of trial names, see the reference list.
Date of download: 10/12/2017